SMARCA4-deficient Malignant Tumors clinical trials at UCSF
1 research study open to eligible people
SMARCA4-deficient malignant tumors are a type of cancer. UCSF is studying how two drugs, nivolumab and ipilimumab, can help treat these tumors in children and young adults. This research is currently open for people to join.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Last updated: